Literature DB >> 12184853

Cyclosporin A improves brain tissue oxygen consumption and learning/memory performance after lateral fluid percussion injury in rats.

Beat Alessandri1, Ann C Rice, Joseph Levasseur, Michelle DeFord, Robert J Hamm, M Ross Bullock.   

Abstract

Traumatic brain injury (TBI) triggers a complex pathophysiological cascade, leading to cell death. A major factor in the pathogenesis of TBI is neuronal overloading with calcium, causing the opening of mitochondrial permeability transition pores (MPTP), which consequently inhibit normal mitochondrial function. The immunosuppressant Cyclosporin A (CsA) has been shown to block MPTPs, and to be neuroprotective in ischemia and TBI. However, the translation of these effects on mitochondrial function, into behavioral endpoints has not been investigated thoroughly. Therefore, we tested the effect of a low, clinically evaluated, CsA dose of 0.125 mg/kg (infused for 3 h) and a higher "known" neuroprotective dose of 18.75 mg/kg on brain tissue O(2) consumption, and on motor and cognitive performance following lateral fluid percussion injury (FPI) in rats. CsA at both concentrations abolished the 25% decrease in O(2) consumption (VO(2)), seen in saline-treated animals at 5 h post-FPI. Furthermore, the lower dose of CsA also ameliorated acute motor deficits (days 1-5 post-FPI) and learning and memory impairments in a Morris water maze test on days 11-15 post-FPI. Although, the higher dose of CsA improved cognitive performance, it worsened acute motor functional recovery. These results suggest, that the CsA-induced preservation of mitochondrial function, as assessed by tissue O(2) consumption, directly translated into improvements in motor and cognitive behavior.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12184853     DOI: 10.1089/08977150260190429

Source DB:  PubMed          Journal:  J Neurotrauma        ISSN: 0897-7151            Impact factor:   5.269


  42 in total

1.  Therapeutic window analysis of the neuroprotective effects of cyclosporine A after traumatic brain injury.

Authors:  Patrick G Sullivan; Andrea H Sebastian; Edward D Hall
Journal:  J Neurotrauma       Date:  2011-02-02       Impact factor: 5.269

2.  Fluid-percussion-induced traumatic brain injury model in rats.

Authors:  Shruti V Kabadi; Genell D Hilton; Bogdan A Stoica; David N Zapple; Alan I Faden
Journal:  Nat Protoc       Date:  2010-08-19       Impact factor: 13.491

Review 3.  Multifunctional drugs for head injury.

Authors:  Robert Vink; Alan J Nimmo
Journal:  Neurotherapeutics       Date:  2009-01       Impact factor: 7.620

Review 4.  Critical appraisal of neuroprotection trials in head injury: what have we learned?

Authors:  Christos M Tolias; M Ross Bullock
Journal:  NeuroRx       Date:  2004-01

5.  Establishing a Clinically Relevant Large Animal Model Platform for TBI Therapy Development: Using Cyclosporin A as a Case Study.

Authors:  Susan S Margulies; Todd Kilbaugh; Sarah Sullivan; Colin Smith; Kathleen Propert; Melissa Byro; Kristen Saliga; Beth A Costine; Ann-Christine Duhaime
Journal:  Brain Pathol       Date:  2015-05       Impact factor: 6.508

Review 6.  Mechanisms of impaired mitochondrial energy metabolism in acute and chronic neurodegenerative disorders.

Authors:  Lucian Soane; Sibel Kahraman; Tibor Kristian; Gary Fiskum
Journal:  J Neurosci Res       Date:  2007-11-15       Impact factor: 4.164

Review 7.  Postischemic oxidative stress promotes mitochondrial metabolic failure in neurons and astrocytes.

Authors:  Gary Fiskum; Camelia A Danilov; Zara Mehrabian; Linda L Bambrick; Tibor Kristian; Mary C McKenna; Irene Hopkins; E M Richards; Robert E Rosenthal
Journal:  Ann N Y Acad Sci       Date:  2008-12       Impact factor: 5.691

8.  Reversal of established traumatic brain injury-induced, anxiety-like behavior in rats after delayed, post-injury neuroimmune suppression.

Authors:  Krista M Rodgers; Yuetiva K Deming; Florencia M Bercum; Serhiy Y Chumachenko; Julie L Wieseler; Kirk W Johnson; Linda R Watkins; Daniel S Barth
Journal:  J Neurotrauma       Date:  2013-11-20       Impact factor: 5.269

9.  Dosing and safety of cyclosporine in patients with severe brain injury.

Authors:  Jimmi Hatton; Bonnie Rosbolt; Philip Empey; Richard Kryscio; Byron Young
Journal:  J Neurosurg       Date:  2008-10       Impact factor: 5.115

10.  Safety and tolerability of cyclosporin a in severe traumatic brain injury patients: results from a prospective randomized trial.

Authors:  Anna Teresa Mazzeo; Gretchen M Brophy; Charlotte B Gilman; Oscar Luís Alves; Jaime R Robles; Ronald L Hayes; John T Povlishock; M Ross Bullock
Journal:  J Neurotrauma       Date:  2009-12       Impact factor: 5.269

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.